Ann: Tasly Receives Approvals For Transaction With MSB, page-8

Mesoblast Ltd (MSB) reported that Tasly Pharmaceutical Group has successfully obtained all necessary approvals, including the Safe Administration of Foreign Exchange, required for closing the investment agreement and the development and collaboration agreement with Mesoblast to commercialize cell therapies for cardiovascular diseases in China. As part of the deal, Mesoblast will receive US$40 million (AUD$54 million) on closing, comprising a US$20 million upfront technology access fee and US$20 million in an equity purchase in Mesoblast at $1.86 per share

http://crweworld.com/article/news-p...sary-approvals-for-transaction-with-mesoblast